Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension

  title={Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension},
  author={E. G. Bevan and John M. Connell and J Doyle and Hugh A. Carmichael and David Lewis Davies and A. Ross Lorimer and Gordon T. Mclnnes},
  journal={Journal of Hypertension},
Objective: To examine the efficacy and tolerability of the neutral endopeptidase inhibitor, candoxatril (UK 79,300) as monotherapy in essential hypertension. Design: Double-blind, placebo-controlled, parallel-group study of 28 days' duration. Setting: Three hospital outpatient departments participating in the Glasgow Blood Pressure Clinic (Glasgow, UK). Patients: Forty patients with essential hypertension with diastolic blood pressure 95–114 mmHg after a 2–4 week placebo run-in period… 

Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients

In salt-sensitive hypertensive patients, omapatrilat demonstrated the hormonal profile of a vasopeptidase inhibitor and lowered ambulatory diastolic and systolic blood pressures more than lisinopril and neither drug had a diuretic, natriurtic, or kaliuretic effect.

Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure

Despite significant activation of the ANP system, reflected by a dose-dependent increase in plasma cyclic GMP concentrations, high doses of candoxatril induced systemic vasoconstrictory rather than vasocilatory effects in patients with CHF, therefore NEP inhibition by candox atril may not exhibit beneficial haemodynamic effects in CHF.

Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.

The detailed integrated renal, hormonal, and hemodynamic effects of acute (first dose) and established (4 days) inhibition of endopeptidase 24.11 by SCH 42495 (200 mg, every 12 hours) were documented

Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.

Candoxatril confers an improvement in exercise capacity in patients with chronic heart failure who are receiving maintenance angiotensin converting enzyme inhibitor therapy.

Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease

  • B. Neal
  • Medicine
    Journal of the renin-angiotensin-aldosterone system : JRAAS
  • 2002
Omapatrilat produced changes in BP, neurohormone and biochemical parameters that were similar for the two doses, and a large-scale randomised trial would be required to reliably establish the effects of omap atrilat on the risks of major vascular disease events among patients with coronary heart disease.

The Therapeutic Potential of Candoxatril, a Neutral Endopeptidase Inhibitor, in Humans

The rationale behind the use of candoxatril in the treatment of hypertension and chronic heart failure in humans and the potential future clinical developments of combined neutral endopeptidase/angiotensin converting enzyme inhibitors are described.

Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

Inhibition of local NEP causes vasoconstriction in forearm resistance vessels of both healthy volunteers and patients with hypertension, which may help to explain the failure of systemic NEP inhibition to lower blood pressure.

Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.

LCZ696 is a novel drug not only for the treatment of heart failure but it is also likely to be a useful antihypertensive drug and may have a preferential effect on systolic pressure.

Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.

Fasidotril, a dual NEP/ACE inhibitor, was an effective oral antihypertensive agent during chronic treatment in high-renin renovascular rats, normal-ren in SHR, and low-renIn DOCA-salt hypertensive rats and in patients with essential hypertension.